Acute liver failure in immunocompetent patients infected with hepatitis E

Christian Wenter · Wegene Borena · Georg Oberhuber · Ivo Graziadei

Received: 1 July 2019 / Accepted: 17 August 2019 / Published online: 6 September 2019 
© The Author(s) 2019

Summary In almost all immunocompetent patients, an acute hepatitis E virus (HEV) infection is clinically silent with spontaneous viral clearance. So far, only a very small number of severe acute HEV infections have been described. This article reports the case of a 78-year-old immunocompetent, diabetic patient, who presented with a symptomatic acute HEV genotype (GT) 3 infection and that progressed to acute liver failure. After starting with an antiviral therapy with ribavirin, the HEV viral load rapidly decreased with a significant improvement of the laboratory parameters as well as a clinical amelioration of the patient. The treatment was continued for 3 months and led to a complete resolution of this acute fulminant hepatitis E. Although the risk is almost negligible this article clearly demonstrates that an acute liver failure due to HEV should also be considered in immunocompetent patients, especially in older male individuals with diabetes mellitus.

Keywords Ribavirin · Zoonotic infection · Solid organ transplantation · Immunosuppression · Liver sausages

Introduction

While in the past hepatitis E virus (HEV) infection was mainly considered as a disease occurring almost exclusively in developing countries and as a travel-associated liver disease in western countries, an increasing number of autochthonous HEV infections have been observed in Europe in recent years [1]. Nowadays, HEV infection is the most common cause of acute viral hepatitis in many European countries. Based on recent seroprevalence data there are at least 2 million locally acquired HEV infections in Europe every year [2–4]. Whereas HEV genotypes (GT) 1 and 2 are obligate human pathogens spread by the fecal-oral route via contaminated water seen in areas with fragile sanitary infrastructure (e.g. Asia, Africa), in high-income countries hepatitis E is mostly a locally acquired zoonotic infection caused almost universally by HEV GT 3, with occasional cases caused by HEV GT 4. Beside HEV positive blood donations as an infection source, an increasing number of animals have been found to carry HEV. Pigs, wild boar and deer seem to be clinically relevant for human health caused by close contact or consumption of infected meat products, which have been undercooked or consumed raw [5].

In almost all immunocompetent patients, the course of the HEV infection is asymptomatic and self-limiting. In recent years only a very small number of cases with severe acute hepatitis progressing to liver failure have been reported; however, mainly in patients affected with the HEV genotype 1 and not with genotype 3 [6]. This article reports the case of an immunocompetent patient who presented with symptomatic acute hepatitis E (GT 3) and progressed to acute liver failure.
Case presentation

In September 2018 a 78-year-old male patient was admitted to this hospital because of increasing itching and progressive fatigue over the previous days. The medical history included heart failure due to ischemic heart disease and an aorto-coronary bypass in 1990; furthermore, diabetes mellitus and arterial hypertension as well as chronic arterial fibrillation. The medication included metformin, lisinopril, bisoprolol and rivaroxaban, which was stopped immediately after admission. Diabetes mellitus was diagnosed in 2013 and was well-controlled. At admission the glycated hemoglobin (HbA1c) level was 5.4%. On examination, the patient’s vital signs were normal, the abdomen was soft without tenderness, but scleral jaundice was present. Blood tests at admission showed significantly elevated aminotransferases and an increased total bilirubin. Liver synthetic functions were within normal limits. Other test results are shown in Table 1.

Due to the still unclear etiology, a liver biopsy was performed indicating an acute hepatitis with portal and lobular inflammation and interface hepatitis but no signs of fibrosis (modified histological activity index, mHAI 9). According to these histological findings, the first differential diagnosis considered was a viral hepatitis but the pathologist could not exclude a drug-induced liver injury (DILI) due to the severity of the histological changes. The hepatitis E serological testing showed positive results for IgM and IgG antibodies (HEV ELISA IgM and IgG, MP Diagnostics, Marburg, Germany) with a high viral load of \(7 \times 10^{12}\) copies/ml confirming the diagnosis of a symptomatic acute HEV infection (RealStar HEV RT-PCR, Altona, Germany). Genotyping revealed the expected GT 3.

As acute HEV infections usually take a self-limiting course in immunocompetent patients with spontaneous clearance in almost all cases, the patient was placed under observation according to international guidelines [7]; however, during the following days liver function tests were as well as liver synthesis parameters significantly deteriorated (see Table 1) and additionally, the patient developed hepatic encephalopathy (grade 2–3 according the West Haven classification) suggesting acute liver failure. Therefore, it was decided to commence ribavirin treatment at a daily dose of 1000 mg as recommended by the EASL guidelines [7].

The treatment with ribavirin was well tolerated and 5 days later a rapid decrease of the aminotransferases, a significant improvement of liver synthesis and of cognitive function were noticed. After 16 days the patient could be discharged in markedly improved clinical condition and was regularly followed-up in the outpatient clinic. At the end of the first month of treatment, the patient presented without any complaints, had normal aminotransferases and a significant improvement of the bilirubin levels, correlating with de-

---

### Table 1

| Variable              | Range  | Admission | Start tx | 5 days tx | Discharge | 1 month tx | End of tx | 3 months after tx D/C |
|-----------------------|--------|-----------|----------|-----------|-----------|------------|------------|-----------------------|
| Bilirubin direct (mg/dl) | 0.01–0.1 | 2.15 | 12.97 | 19.37 | 19.83 | 5.38 | 0.83 | –                     |
| Bilirubin total (mg/dl) | 0.2–1.1 | 3.47 | 18.75 | 27.23 | 27.34 | 5.89 | 1.47 | 1.03                 |
| AST (U/l)             | 10–50 | 466 | 2080 | 413 | 219 | 31 | 16 | 19                     |
| ALT (U/l)             | 10–50 | 596 | 3044 | 1272 | 795 | 49 | 10 | 17                     |
| AP (U/l)              | 40–129 | 187 | 175 | 167 | 167 | 133 | 74 | 71                     |
| PT (%)                | 70–120 | 76 | 44 | 89 | 86 | N.A. | 40a | 40a                   |
| INR                   | – | 1.19 | 1.9 | 1.07 | 1.10 | 2.36a | 1.89a | 1.94a              |
| Alb (g/dl)            | 3.5–5.0 | 4.3 | 4.0 | 3.8 | N.A. | 3.6 | 4.0 | 4.5                   |
| Creatinine (mg/dl)    | 0.7–1.2 | 1.02 | 0.99 | 0.95 | 0.96 | 0.8 | 0.92 | 1.05                  |
| Hemoglobin (g/dL)     | 14.0–17.5 | 14.8 | 14.3 | 15.2 | 15.1 | 12.4 | 13.9 | 14.4                |
| Platelets (10^9/L)    | 150–350 | 205 | 359 | 387 | 374 | 273 | 234 | 225                  |
| LDH (U/l)             | 135–225 | 324 | 416 | 196 | 186 | 150 | 181 | 161                  |
| HEV-RNA (copies/ml)   | – | – | \(7 \times 10^{12}\) | – | – | 1.1 \times 10^2 | N.D. | N.D.               |

*aOral anticoagulation therapy (rivaroxaban)*  
*AST aspartate aminotransferase, ALT alanine aminotransferase, AP alkaline phosphatase, LDH lactate dehydrogenase, INR international ratio, PT prothrombin*  
time, tx treatment, D/C discontinuation, N. D. not detectable, N. A. not available, HEV-RNA hepatitis E virus - ribonucleotide acid
creased HEV-PCR values (see Table 1). After 3 months of antiviral therapy, HEV RNA was undetectable and therefore, ribavirin treatment was stopped. At the last follow-up visit in March 2019, the patient felt very comfortable, all laboratory parameters were within the normal range and the HEV PCR was still negative suggesting a complete virologic response and a complete recovery from the acute fulminant hepatitis E.

Regarding possible routes of infection, the patient denied any consumption of poorly cooked pork, wild boar or deer meat; however, he remembered consuming a mortadella sausage (local sausage specialty containing raw pork meat) some 6 weeks before admission. As there is evidence of high HEV prevalence in liver sausages and raw meat sausages [8], it was assumed that the consumption of a mortadella sausage was the route of infection in the patient.

Discussion

Hepatitis E infection is an emerging global public health problem. Over the last years there has been a paradigm shift from an infection of developing countries (GT 1, 2) to an endemic locally acquired zoonotic infection (GT 3, 4) and HEV infections have become the major cause of acute viral hepatitis in many European countries [2]. In the majority of cases, acute HEV infections are asymptomatic with spontaneous clearance of the virus. Chronic courses with progression to liver cirrhosis and chronic liver failure were described only in immunosuppressed patients, in particular in solid organ transplant recipients. In contrast to these findings, the male patient in the present case developed a symptomatic acute HEV infection with GT 3 and progressed to acute liver failure. This case confirms a very small number of HEV infection with GT 3 and progressed to acute liver failure, it was decided to start treatment with ribavirin, although it cannot be proved retrospectively if the patient would have recovered without treatment. In accordance with the abovementioned cases [11], ribavirin treatment was associated with a rapid normalization of liver enzymes, an improvement of liver function and complete clearance of HEV-RNA in the patient. A European retrospective, multicenter study demonstrated that in patients with underlying hematological malignancies (42% with allogeneic hematopoietic stem cell transplantation) only early ribavirin treatment for acute HEV infections was associated with a better outcome [12]. It is assumed that ribavirin inhibits HEV replication by depleting guanosine triphosphate pools [13]. In solid organ transplant recipients, it has been shown that mycophenolic acid can be associated with spontaneous HEV clearance [6]. In individual patients with acute liver failure, who were retrospectively identified as HEV-related cases, corticosteroid treatment was associated with improved liver function parameters [14]; however, due to insufficient evidence, corticosteroid treatment cannot be supported for the treatment of HEV infection. Thus, ribavirin is the only currently established therapeutic option for HEV-induced acute or chronic hepatitis.

Frequently, it is difficult to identify the source of infection. Beside blood products, the consumption of undercooked or raw pork, wild boar or deer meat as well as liver is the main source for HEV infection in humans. Interestingly, the present patient consumed a mortadella sausage, which contains raw pork meat, approximately 6 weeks before admission. In a German study, HEV was found in about 10% of raw sausages and liver sausages in retail [15]. These data were confirmed by screening of ready to eat meat products for HEV in Switzerland demonstrating a HEV prevalence of 18.9% in liver sausages and 5.7% of raw meat sausages [8]. Therefore, the EASL clinical practice guidelines recommend avoiding the consumption of undercooked meat (e.g. pork, wild boar and venison) and shellfish in immunocompromized individuals and patients with chronic liver disease [7, 16]. For the general (immunocompetent) population, however, this recommendation is currently not justified and further data are needed, especially regarding older diabetic males with or without underlying liver disease [9, 10].

This article clearly demonstrates that all patients with acute hepatitis should be screened for hepatitis E infection. Additional studies are necessary to figure out which patients are especially prone to develop progressive liver disease and who might actually benefit from or show an urgent need for viral treatment.

Funding

Open access funding provided by University of Innsbruck and Medical University of Innsbruck.

Compliance with ethical guidelines

Conflict of interest C. Wenter, W. Borena, G. Oberhuber, and I. Graziadei declare that they have no competing interests.
Ethical standards  An informed consent to publish this anonymized case was given by the patient.

Open Access  This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Kamar N, Bendall R, Legrand-Abravanel F, et al. Hepatitis E. Lancet. 2012;379:2477–88.
2. Adlhoch C, Avellan A, Baylis SA, et al. Hepatitis E virus: assessment of the epidemiological situation in humans in Europe, 2014/15. J Clin Virol. 2016;82:9–16.
3. Hewitt PE, Ijaz S, Brailsford SR, et al. Hepatitis E virus in blood components: a prevalence and transmission study in southeast England. Lancet. 2014;384:1766–73.
4. Bura M, Lagiedo M, Michalak M, Sikora J, Mozek-Lisewska I. Hepatitis E virus IgG seroprevalence in HIV patients and blood donors, west central Poland. Int J Infect Dis. 2017;61:20–2.
5. Kamar N, Dalton HR, Abravanel F, Izopet J. Hepatitis E virus infection. Clin Microbiol Rev. 2014;27:116–38.
6. Pischke S, Wedemeyer H. Hepatitis E virus infection: multiple faces of an underestimated problem. J Hepatol. 2013;58:1045–6.
7. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on hepatitis E virus infection. J Hepatol. 2018;68:1256–71.
8. Moor D, Liniger M, Baumgartner A, Felleisen R. Screening of ready-to-eat meat products for hepatitis E virus in Switzerland. Food Environ Virol. 2018;10:263–71.
9. Dalton HR, Stableforth W, Thurairajah P, et al. Autochthonous hepatitis E in Southwest England: natural history, complications and seasonal variation, and hepatitis E virus IgG seroprevalence in blood donors, and the elderly patients with chronic liver disease. Eur J Gastroenterol Hepatol. 2008;20:784–90.
10. Dalton HR, Bendall RP, Rashid M, et al. Host risk factors and autochthonous hepatitis E infection. Eur J Gastroenterol Hepatol. 2011;23:1200–5.
11. Peron JM, Dalton HR, Izopet J, Kamar N. Acute autochthonous hepatitis E in western patients with underlying chronic liver disease: a role for Ribavirin? J Hepatol. 2011;54:1323–4.
12. Von Felden J, Alric L, Pischke S, et al. The burden of hepatitis E among patients with haematological malignancies: a retrospective European cohort study. J Hepatol. 2019; https://doi.org/10.1016/j.jhep.2019.04.022.
13. Debing Y, Emerson SU, Wang Y, et al. Ribavirin inhibits in vitro hepatitis E virus replication through depletion of celllular GPT pools and is moderately synergistic with alpha interferon. Antimicrob Agents Chemother. 2014;58:267–73.
14. Manka P, Bechmann LP, Coombes JD, et al. Hepatitis E virus infection as a possible cause of acute liver failure in Europe. Clin Gastroenterol Hepatol. 2015;13:1836–1842.e2. quiz e1157–e1838.
15. Szabo K, Trojan E, Anheyer-Behmenburg H, et al. Detection of hepatitis E virus RNA in raw sausages and liver sausages from retail in Germany using an optimized method. International Journal of Food Microbiology. 2015;215:149–56.
16. Legrand-Abravanel F, Kamar N, Sandres-Saune K, et al. Characteristics of autochthonous hepatitis E virus infection in solid-organ transplant recipients in France. J INFECT DIS. 2010;202:835–44.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.